Information Provided By:
Fly News Breaks for February 21, 2017
TRVN
Feb 21, 2017 | 11:47 EDT
After Trevena's oliceridine hit on two primary Phase III endpoints, Jefferies analyst Biren Amin says the debate is around the painkiller's commercial prospects with the stock 34% to $4.72 in midday trading. Oliceridine can be approved in late 2018 and the clinical profile overall should justify a health outcomes benefit, Amin tells investors in a research note. He highlights the drug's improved safety profile relative to morphine in today's data. The analyst keeps a Buy rating on Trevena with an $11 price target.
News For TRVN From the Last 2 Days
There are no results for your query TRVN
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.